Overview

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Phase:

Phase 1

Details

Lead Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company